医学
类风湿性关节炎
许可证
抗风湿药
药品审批
药物治疗
重症监护医学
药理学
内科学
药品
政治学
法学
出处
期刊:Drugs
[Springer Nature]
日期:2022-12-13
卷期号:83 (1): 87-92
被引量:35
标识
DOI:10.1007/s40265-022-01821-0
摘要
Ozoralizumab (Nanozora®), a trivalent anti-tumour necrosis factor alpha (TNFα) NANOBODYⓇ compound, has been developed by Taisho Pharmaceutical Co. Ltd (under license from Ablynx, an affiliate of Sanofi) for the treatment of rheumatoid arthritis (RA). In September 2022, ozoralizumab was approved in Japan for the treatment of RA that is inadequately managed by current available treatments. This article summarizes the milestones in the development of ozoralizumab leading to this first approval.
科研通智能强力驱动
Strongly Powered by AbleSci AI